bevacizumab

Overview

Bevacizumab (trade name Avastin) is a recombinant humanized monoclonal IgG1 antibody used as an anti-angiogenic therapy, chiefly in oncology. It binds vascular endothelial growth factor A (VEGFA) with high affinity and prevents it from engaging its receptors VEGFR-1 and VEGFR-2, blocking the signaling that drives new vessel formation in tumors. Because it neutralizes the ligand in the extracellular space, its mechanism differs from that of small-molecule tyrosine kinase inhibitors such as sorafenib, lenvatinib or cabozantinib, which act on receptor kinase domains inside the cell — a distinction that matters for toxicity, since the antibody hits one ligand while the kinase inhibitors hit many targets at once. Approved in 2004, it is given intravenously, generally in combination, across colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, ovarian cancer and cervical cancer, paired with cytotoxic backbones such as irinotecan, carboplatin and paclitaxel, or cisplatin plus paclitaxel; in cervical cancer the alternative backbone is topotecan plus paclitaxel rather than fluorouracil-containing regimens. Anti-VEGF agents of this class, including Ranibizumab and aflibercept, are also given intravitreally in retinal vascular disease, where bevacizumab itself is widely used off-label at a fraction of the cost.

Beyond suppressing angiogenesis, VEGFA blockade remodels the tumor microenvironment. Vascular normalization can improve perfusion and drug delivery, while reduced VEGF signaling lessens the immunosuppression VEGF exerts on dendritic cells, regulatory T cells and myeloid populations — the rationale for combining it with checkpoint inhibitors. The combination with the PD-L1 antibody atezolizumab is now first-line standard of care for unresectable hepatocellular carcinoma, and analogous immunotherapy-plus-antiangiogenic strategies are under study with pembrolizumab and durvalumab.

The toxicities follow from blocking a pathway that healthy tissue also uses: hypertension and proteinuria from effects on endothelium and glomerulus, impaired wound healing that requires surgery to be spaced around dosing, arterial and venous thrombosis, bleeding — of particular concern in cirrhotic patients with portal hypertension — and, uncommonly but seriously, gastrointestinal perforation. Combined immune-targeted regimens add immune-related toxicities on top of these. Bevacizumab's capacity to reduce vascular permeability and edema has also prompted non-oncologic use, for instance in radiation-induced tissue injury.

Recent Publications Summary (latest 30 papers)

hepatocellular carcinoma (HCC) remains the primary disease focus in recent bevacizumab literature, particularly with atezolizumab plus bevacizumab as first-line immunotherapy. Real-world evidence demonstrates both efficacy and clinical challenges with this regimen. In a UK Midlands cohort of 233 patients, median overall survival was 16.5 months with a 42.9% objective response rate; however, treatment discontinuation occurred in 81.5% of patients, most commonly due to disease progression (47.4%), toxicity (22.6%), or liver decompensation (17.9%), with 39.1% receiving second-line therapy 42477572Jul. A prospective French CHIEF cohort examined second-line treatment outcomes following atezolizumab-bevacizumab 42276189Jun. Comparative analyses have identified baseline des-γ-carboxy prothrombin (DCP) as a potential biomarker to guide selection between atezolizumab-bevacizumab and durvalumab-tremelimumab regimens 42477505Jul, while early-to-late survival dynamics analyses examined temporal benefit differences between these first-line combinations 42068971May. Cost-effectiveness studies in the Chinese healthcare system demonstrated favorable outcomes for finotonlimab plus bevacizumab compared to sorafenib 42505057Jul42133639May. Response assessment comparisons in HCC patients receiving atezolizumab-bevacizumab showed that both RECIST 1.1 and modified RECIST reliably predicted overall survival outcomes 42062227Apr.

Expansion of bevacizumab-containing immunotherapy regimens reflects ongoing optimization efforts in HCC treatment. The phase 2 PRODIGE 81-FFCD 2101-TRIPLET HCC trial investigated adding ipilimumab to atezolizumab plus bevacizumab for unresectable HCC in a first-line setting 42330996Jun. For patients progressing on atezolizumab-bevacizumab, balloon-occluded alternative infusion transarterial chemoembolization was explored as a salvage strategy for refractory disease 42373279Jun. Second-line durvalumab plus tremelimumab was directly compared with lenvatinib following first-line atezolizumab-bevacizumab in unresectable HCC 42096473May. A multinational LITCHI registry study demonstrated that 15 of 18 patients underwent successful liver transplantation after atezolizumab-bevacizumab, with one-year survival of 77%, and despite most patients exceeding Milan criteria before immunotherapy initiation, HCC recurrence occurred in only one patient 42156355May. Pharmacovigilance analyses detected distinct adverse event signals with atezolizumab-bevacizumab, including fulminant type-1 diabetes mellitus, myositis, encephalitis, and myocarditis 42461453Jul.

Bevacizumab efficacy and mechanisms have been investigated across multiple cancer types and patient populations. In elderly patients (≥75 years) with advanced colorectal cancer, trifluridine/tipiracil with or without bevacizumab achieved median relative dose intensities of 72.9% and 74.8% respectively, with grade ≥3 neutropenia occurring in 60.5–81.8% of patients 42599544Aug. In EGFR-amplified metastatic tumors, erlotinib plus bevacizumab yielded a clinical benefit rate of 44% across diverse histologies including colorectal cancer and glioblastoma, with median progression-free survival of 3.7 months 42298055Jun. tumor-educated platelet gene signatures showed preliminary utility for predicting bevacizumab response in colorectal cancer, suggesting potential biomarker-guided therapy selection 42375537Jun. In elderly patients with driver gene-negative advanced lung adenocarcinoma, first-line bevacizumab plus chemotherapy conferred median overall survival of 47 months and progression-free survival of 24 months 42499069Jul. A randomized phase III APPLE trial reported long-term outcomes (3.5 years follow-up) of atezolizumab and platinum-pemetrexed with or without bevacizumab for advanced nonsquamous non-small cell lung cancer 42127535May. The INDUCE trial (JBCRG-M10) investigated bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in programmed death-ligand 1-positive metastatic triple-negative breast cancer to overcome vascular endothelial growth factor-associated resistance mechanisms 42128502May.

Mechanistic and resistance studies have clarified bevacizumab's molecular effects and therapeutic limitations across diseases. In glioblastoma cells, bevacizumab induced dose-dependent apoptosis through upregulation of miR-4695-5p, which suppressed PKMYT1 expression 42133791May. Bevacizumab resistance in ovarian cancer was driven by ENO1 lactylation-mediated metabolic reprogramming and enhanced angiogenesis, with AARS1-catalyzed lactylation promoting lactate synthesis and histone lactylation marks 42134086May. Beyond cancer, bevacizumab demonstrated renoprotective potential against sepsis-induced acute kidney injury through modulation of inflammatory responses and pyroptosis signaling in a murine polymicrobial sepsis model 42201618May, and preliminary evidence suggested efficacy for radiation-induced (radiculo)plexopathy 42206990May. Analytical and characterization methods have advanced bevacizumab assessment, including hyperspectral micro-Raman spectroscopy for quantification in human blood serum 42108066May, single-protein oscillator technology for simultaneous size and charge measurement to detect aggregation states 42126207May, and hydrodynamic molecular weight modeling via dynamic light scattering to assess oligomerization in formulations 42373916Jun.

What Changes, What Holds

1. Real-world hepatocellular carcinoma cohorts show 81.5% treatment discontinuation from atezolizumab-bevacizumab despite its first-line designation
NEW DIRECTION Des-γ-carboxy prothrombin levels identify patients benefiting from atezolizumab-bevacizumab versus durvalumab-tremelimumab 42477505Jul42477572Jul. The baseline establishes this regimen as first-line standard of care but does not address real-world discontinuation patterns (disease progression 47.4%, toxicity 22.6%, decompensation 17.9%) or biomarker-guided selection, now emerging as critical to optimizing this population's management.

2. atezolizumab-bevacizumab enables liver transplantation in advanced hepatocellular carcinoma, achieving 77% one-year post-transplant survival despite exceeding Milan criteria
NEW DIRECTION Fifteen of eighteen registry patients progressed from this regimen to transplantation with only one HCC recurrence 42156355May. The baseline positions this drug pairing as extending survival in unresectable HCC; these findings reposition it as a bridge-to-cure strategy rather than purely palliative therapy. Pharmacovigilance concurrently detected rare immune toxicities including fulminant type-1 diabetes, myositis, and encephalitis 42461453Jul.

3. tumor-educated platelet signatures and sequential bevacizumab-paclitaxel induction predict response and overcome VEGF-associated resistance across solid tumors
NEW DIRECTION Platelet gene signatures forecast bevacizumab efficacy in colorectal cancer 42375537Jun, while induction with bevacizumab-paclitaxel preceding atezolizumab and nab-paclitaxel improves outcomes in programmed death-ligand 1-positive triple-negative breast cancer by bypassing VEGF-driven immunotherapy resistance 42128502May. The baseline describes bevacizumab's efficacy across tumor types but omits biomarker-guided patient selection or this induction sequencing strategy.

4. ENO1 lactylation-mediated metabolic reprogramming drives bevacizumab resistance in ovarian cancer through renewed angiogenesis
NEW DIRECTION AARS1-catalyzed lactylation of ENO1 promotes lactate synthesis and metabolic reprogramming, enabling enhanced angiogenesis despite bevacizumab exposure 42134086May. The baseline explains resistance through microenvironmental remodeling but identifies no specific molecular drivers in ovarian cancer. Separately, renoprotection against sepsis-induced acute kidney injury through pyroptosis modulation expands non-oncologic applications beyond radiation-induced tissue injury documented in the baseline 42201618May.

Overview update candidates: Entries 1 and 2.